The Weekly Roundup: November 24-28

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Q4 Investment Planning: What to Do Now to Reduce What You Owe in 2026

Discover 5 effective tax-saving strategies for investors in dermatology, enhancing portfolio management and planning for 2026 with OJM Group's expert insights.

Mondana Ghias, MD, FAAD, on Redefining Virtual Subspecialty Dermatology

Tono Health revolutionizes virtual dermatology by enhancing specialist access for HS and oncodermatology care, while prioritizing the doctor-patient relationship.

Rapid Onset and Reliable Results: Rosalyn George, MD’s Look at TrenibotE and the Consistency of Botox

Discover the latest advancements in botulinum toxins, including TrenibotE's rapid effects and onabotulinumtoxinA's consistent results for aesthetic treatments.

INF904 Demonstrates Biologic-Like Efficacy in HS and CSU

Discover the potential of INF904, a groundbreaking oral therapy targeting C5aR for hidradenitis suppurativa and chronic spontaneous urticaria, promising new treatment options.

Tralokinumab Shows Durable Efficacy and Safety Through 32 Weeks in Phase 3b ADHAND Trial

LEO Pharma reveals promising 32-week results for tralokinumab in treating atopic dermatitis on hands, enhancing patient quality of life and safety.

Elevate-Derm Takeaways: Acne Innovation, Alopecia Care, and Cross-Specialty Insights

James Canner, PA-C, outlines key updates in acne therapeutics, alopecia management, and rheumatology–dermatology collaboration presented at Elevate-Derm Fall.

Network Meta-Analysis Identifies Most Effective CHE Therapy

High-dose topical delgocitinib significantly outperformed oral alitretinoin in reducing HECSI severity at both 12 and 16 weeks.

Q&A: Des Fernandes, MB. BCH, FRCS, on Pioneering Modern Microneedling

Discover how Des Fernandes, MB. BCH, FRCS, revolutionized microneedling and regenerative skin care, enhancing results with topical vitamins for optimal skin health.

Clear Communication Helps Reduce Patient Concerns About Boxed Warnings

Michael Lewitt, MD, reassures patients that topical ruxolitinib shows minimal systemic absorption despite sharing a mechanism with oral JAK inhibitors.

Improving Chronic Hand Eczema Care With a Multifactorial Approach

At Elevate-Derm 2025, Lisa Weiss, MMSc, PA-C, outlined the multifactorial approach to CHE, the clinical utility of delgocitinib, and her expanding educational and leadership priorities heading into 2026.

Journal Digest: November 26, 2025

This review of the latest dermatologic studies highlights new research from this week, including immune checkpoint inhibitors in acral melanoma, the link between skin microbiota and asthma, and more.

Expert Insights on Neurotoxins for Mature Skin

Experts reveal how neurotoxins enhance mature skin, emphasizing precision and lower doses for natural, youthful results.

Dermatology and Podiatry Collaboration Expands Clinical Insight and Professional Opportunity

At Elevate-Derm, Shanna Miranti, MPAS, PA-C, and Larissa Schmidt, DPM, outlined how interdisciplinary education, shared therapeutic advances, and evolving career pathways are strengthening the connection between dermatology and podiatry.

The Aesthetic Edge: November 2025

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of November.

Interview Intersection: Expert Interviews From November 2025

Dermatology Times is recapping our exclusive expert interviews from the month of November.

2025 Elevate-Derm Fall: Full Conference Recap

The 2025 Elevate-Derm Fall Conference recently concluded in Tampa, Florida. Dermatology Times was live on site to interview presenters about their latest clinical updates and what’s on the horizon in dermatology.

Dermatology Times November 2025 Print Recap

Learn more about the in-depth topics covered in the November 2025 print issue of Dermatology Times.

ASDS 2025: Top Treatments and Trends

Discover the latest trends in aesthetic medicine from ASDS 2025, focusing on safer treatments, improved skin quality, and innovative injectables.

Dermatology Times November 2025 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of November.

Topical Pan-JAK Inhibitor LNK01004 Shows Promising Efficacy and Safety in Phase 2 AD Trial

Lynk Pharmaceuticals reveals promising phase 2 trial results for LNK01004, a topical treatment showing efficacy and safety in moderate-to-severe atopic dermatitis.

Top 5 Articles of the Month: November 2025

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.